共 121 条
[1]
Cardoso F(2014)ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) Breast 23 489-502
[2]
Costa A(2012)Everolimus in postmenopausal hormone-receptor–positive advanced breast cancer N Engl J Med 366 520-529
[3]
Norton L(2016)Palbociclib and letrozole in advanced breast cancer N Engl J Med 375 1925-1936
[4]
Senkus E(2016)Ribociclib as first-line therapy for HR-positive, advanced breast cancer N Engl J Med 375 1738-1748
[5]
Aapro M(2017)MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR +/HER2− advanced breast cancer who had progressed while receiving endocrine therapy J Clin Oncol 35 2875-2884
[6]
Andre F(2005)Never too old? Age should not be a barrier to enrollment in cancer clinical trials Oncologist 10 198-204
[7]
Baselga J(2016)Accrual of older patients with breast cancer to alliance systemic therapy trials over time: protocol A151527 J Clin Oncol 35 421-431
[8]
Campone M(2016)Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial Lancet Oncol 17 425-439
[9]
Piccart M(2016)Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18 Breast Cancer Res 18 67-998
[10]
Burris HA(2013)Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial Lancet Oncol 14 989-444